Where Tech Meets Bio
Subscribe
Sign in
Home
Weekly Highlights
Deep Dives
Sponsored Features
About
Latest
Top
Discussions
Cancer as a Data Problem: What AI Is Doing in Oncology
We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to…
Feb 27
•
BiopharmaTrend
35
5
Is “Rescuing Failed Drugs with AI” a Category Now?
Inside the growing bet that AI can find the patients pharma's failed trials missed...
May 21
•
Andrii Buvailo, PhD
and
Roman Kasianov
31
4
3
Five Genomics Watchpoints for 2026
Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one…
Feb 20
•
BiopharmaTrend
30
3
2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic
Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech…
Jan 15
•
BiopharmaTrend
31
4
9
The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.
Mar 7
•
BiopharmaTrend
30
5
Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape
Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development
Nov 20, 2025
•
Andrii Buvailo, PhD
28
3
5
Everyone is Launching AI Agents. What's Being Deployed?
A check-in on biopharma's agentic AI buildout
Apr 4
•
Roman Kasianov
and
Andrii Buvailo, PhD
21
2
4
From Biohacking to Healthcare: The Growing Pains of the Longevity Industry
Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…
Apr 16
•
Louise von Stechow
and
BiopharmaTrend
24
2
5
New LLMs, Agents, and Graphs in Life Sciences
With Claude joining the lab, we survey healthcare LLMs, their real-world use, and how neurosymbolic AI can remedy their limitations
Nov 6, 2025
•
BiopharmaTrend
24
2
Big Pharma’s China Deal Wave & 12 Companies on Our Radar
A snap look at some of the deal dynamics and company platforms pulling global pharma toward China
Feb 9
•
BiopharmaTrend
22
3
New-Modality Drugs Behind Today’s Big Headlines
How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets
Feb 12
•
BiopharmaTrend
20
3
The '4th Wave' of AI Drug Discovery is Here, According to This Report
I’ve come across a really well-put report on the evolving state of artificial intelligence (AI) in drug discovery in 2024 and beyond, authored by Chris…
Dec 12, 2024
•
Andrii Buvailo, PhD
24
5
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
